ClinicalTrials.gg
TerminatedNCT01405950Updated Jun 17, 2013Results posted

Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

A Phase 1 interventional study of Zanaflex Capsules and Zanaflex Capsules in Spasticity Due to Cerebral Palsy, sponsored by Acorda Therapeutics. Terminated at 1 site in United States. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2013-06-17.

Sponsored by Acorda Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
Please see 'Further study details as provided by Acorda Therapeutics' for explanation of why study stopped.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 372 studies in Cerebral Palsy with a site in United States — 75 open to participants now, 103 under way, none of them phase 3. Cerebral Palsy · United States.

Enrollment
223rd of 296
10 · median 25
Started
2011
with 8 others
Phase 1
25 of 372
5 open now
Registered
71st of 372
by date

Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 223rd largest by enrollment of the 296 interventional ones that give a count, is one of 9 that started in 2011, is one of 25 in phase 1, and was the 71st registered.

Cerebral Palsy

1,939 studies on the registry are indexed under Cerebral Palsy; 457 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

75 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 269 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 234 (87%) stop at 75 or younger; 254 take children under 18; 52 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 372 studies in Cerebral Palsy with a site in United States, or all of them as a file.
02

Study summary

A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.

Read the detailed description

Evaluation of the study's progress after the amendment remained challenging with continued pre-screen failures noted in areas of Botox injection inclusion; family participation refusal / disinterest and gastric or jejunostomy tube placement. A third protocol amendment to improve enrollment was discussed with the Investigators who did not believe further amendment would overcome the barriers expressed by parents that would subject their children to an intense study time commitment without direct benefit. The investigative sites were notified that the study was closed to enrollment March 27, 2012.

03

Conditions studied

  • Spasticity Due to Cerebral Palsy

Browse trials for

04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have clinically diagnosed spasticity resulting from cerebral palsy
  • Have a motor disability resulting from a static, nonprogressive brain injury or malformation occurring prenatally or before the age of 2 years
  • Have mild to moderate spasticity at screening
  • Have a parent or legally accepted representative able to understand and comply with study requirements who voluntarily provides and agrees to be primarily responsible for adhering to the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Have a history of or allergic reaction to tizanidine or any of the capsule components
  • Have dietary restrictions or food allergies that conflict with a standardized meal
  • Have psychiatric, gastrointestinal, pulmonary, hematologic, endocrine, cardiovascular, renal, or hepatic disease that requires pharmacologic intervention
  • Have an ongoing seizure disorder that requires medical therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Dose Level 1

    Drug: Zanaflex Capsules

  • Experimental
    Dose Level 2

    Drug: Zanaflex Capsules

  • Experimental
    Dose Level 3

    Drug: Zanaflex Capsules

  • Experimental
    Dose Level 4

    Drug: Zanaflex Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter AUC0-8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.

    Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).

    Time frame: Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.

    Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).

    Time frame: Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours

07

Results

Posted May 13, 2013

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2Dose Level 3Dose Level 4
Started8200
Completed7200
Not completed1000
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryPharmacokinetic (PK) Parameter AUC0-8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.

Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).

Time frame:
Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours
Reported as:
Mean · hour*nanogram/mililiter
Pharmacokinetic (PK) Parameter AUC0-8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.
hour*nanogram/mililiterDose Level 1Dose Level 2Dose Level 3Dose Level 4
Pharmacokinetic (PK) Parameter AUC0-8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.5.60 ± 1.796.11 ± 1.29——
SecondaryPharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.

Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).

Time frame:
Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours
Reported as:
Mean · nanogram/mililiter
Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.
nanogram/mililiterDose Level 1Dose Level 2Dose Level 3Dose Level 4
Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.1.87 ± 0.605.29 ± 0.05——

Adverse events

Collected over Up to 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1—0/8 (0%)1/8 (12.5%)
Dose Level 2—0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventDose Level 1Dose Level 2
SomnolenceNervous system disorders1/82/2
Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders0/81/2

Baseline characteristics

Age, Customized
Age, Customized(participants)Dose Level 1Dose Level 2Total
2-3 years303
4-5 years101
6-12 years325
13-16 years101
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Total
Female516
Male314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Level 1Dose Level 2Total
Hispanic or Latino000
Not Hispanic or Latino8210
Unknown or Not Reported000
08

Study locations

1 site
  • University of Louisville Department of Neurology dba Kentucky Neuroscience Research Health Care Outpatient Center (HCOC)
    Louisville, Kentucky 40202, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2011
First posted
Jul 29, 2011
Start
May 2011
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results first posted
May 13, 2013
Last update
Jun 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01405950
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Jul 29, 2011
Start date
May 2011
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
May 13, 2013
Last update
Jun 17, 2013

Study contacts

Herbert Henney, PharmD
study director · Acorda Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tizanidine

Start the discussion